New PET imaging agent alters prostate cancer plan for more than 40% of patients
A recently developed PET imaging agent is earning praise following positive clinical trial results in men with high-risk prostate cancer.
North Billerica, Massachusetts-based Lantheus presented early findings from a study at the recent American Urological Association virtual meeting. The PSMA-targeted agent—piflufolastat F-18—detected disease that had spread outside the prostate in nearly one-third of men.
Additionally, an independent, retrospective review showed the imaging agent led to possible changes in care management strategy for 43.6% of patients, including decisions regarding surgery or radiation therapy.